Cristian Massacesi
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Cristian Massacesi
Bristol Myers Squibb Co reported in an 8-K filed July 25, 2025 that Cristian Massacesi was appointed Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. The proxy statement of Bristol Myers Squibb Co reports total compensation of $10,072,950 for Cristian Massacesi in fiscal 2025, including a base salary of $388,462. Cristian Massacesi has spoken on 1 earnings call across 1 company, most recently for Bristol Myers Squibb Co on April 30, 2026.
“Bristol Myers Squibb (NYSE: BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Bristol Myers Squibb Co (BMY)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Bristol Myers Squibb Co
Other people whose current roles at this company are on record from its filings.
- Christopher Boerner CEO, COO, Board Member
- Christopher Boerner, Ph.D. CEO, COO, Board Member
- David Elkins CFO
- Sandra Leung General Counsel
- Deepak L. Bhatt, M.D., M.P.H. Board Member
- Derica W. Rice Board Member
- Manuel Hidalgo Medina Board Member
- Michael R. McMullen Board Member
- Paula A. Price Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Bristol Myers Squibb Co (BMY) | M.D. EVP, Chief Medical Officer, Head of Development | $388,462 | $10,072,950 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.